Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
15 "Receptors"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Article image
Comparison of tissue-based and plasma-based testing for EGFR mutation in non–small cell lung cancer patients
Yoon Kyung Kang, Dong Hoon Shin, Joon Young Park, Chung Su Hwang, Hyun Jung Lee, Jung Hee Lee, Jee Yeon Kim, JooYoung Na
J Pathol Transl Med. 2025;59(1):60-67.   Published online January 15, 2025
DOI: https://doi.org/10.4132/jptm.2024.10.01
  • 869 View
  • 130 Download
AbstractAbstract PDF
Background
Epidermal growth factor receptor (EGFR) gene mutation testing is crucial for the administration of tyrosine kinase inhibitors to treat non–small cell lung cancer. In addition to traditional tissue-based tests, liquid biopsies using plasma are increasingly utilized, particularly for detecting T790M mutations. This study compared tissue- and plasma-based EGFR testing methods.
Methods
A total of 248 patients were tested for EGFR mutations using tissue and plasma samples from 2018 to 2023 at Pusan National University Yangsan Hospital. Tissue tests were performed using PANAmutyper, and plasma tests were performed using the Cobas EGFR Mutation Test v2.
Results
All 248 patients underwent tissue-based EGFR testing, and 245 (98.8%) showed positive results. Of the 408 plasma tests, 237 (58.1%) were positive. For the T790M mutation, tissue biopsies were performed 87 times in 69 patients, and 30 positive cases (38.6%) were detected. Plasma testing for the T790M mutation was conducted 333 times in 207 patients, yielding 62 positive results (18.6%). Of these, 57 (27.5%) were confirmed to have the mutation via plasma testing. Combined tissue and plasma tests for the T790M mutation were positive in nine patients (13.4%), while 17 (25.4%) were positive in tissue only and 12 (17.9%) in plasma only. This mutation was not detected in 28 patients (43.3%).
Conclusions
Although the tissue- and plasma-based tests showed a sensitivity of 37.3% and 32.8%, respectively, combined testing increased the detection rate to 56.7%. Thus, neither test demonstrated superiority, rather, they were complementary.
Article image
Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer
Ye Sul Jeong, Jun Kang, Jieun Lee, Tae-Kyung Yoo, Sung Hun Kim, Ahwon Lee
J Pathol Transl Med. 2020;54(1):87-94.   Published online November 13, 2019
DOI: https://doi.org/10.4132/jptm.2019.10.14
  • 7,614 View
  • 204 Download
  • 17 Web of Science
  • 18 Crossref
AbstractAbstract PDF
Background
Accurate molecular classification of breast core needle biopsy (CNB) tissue is important for determining neoadjuvant systemic therapies for invasive breast cancer. The researchers aimed to evaluate the concordance rate (CR) of molecular subtypes between CNBs and surgical specimens.
Methods
This study was conducted with invasive breast cancer patients who underwent surgery after CNB at Seoul St. Mary’s Hospital between December 2014 and December 2017. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 were analyzed using immunohistochemistry. ER and PR were evaluated by Allred score (0–8). HER2 was graded from 0 to +3, and all 2+ cases were reflex tested with silver in situ hybridization. The labeling index of Ki67 was counted by either manual scoring or digital image analysis. Molecular subtypes were classified using the above surrogate markers.
Results
In total, 629 patients were evaluated. The CRs of ER, PR, HER2, and Ki67 were 96.5% (kappa, 0.883; p<.001), 93.0% (kappa, 0.824; p<.001), 99.7% (kappa, 0.988; p<.001), and 78.7% (kappa, 0.577; p<.001), respectively. Digital image analysis of Ki67 in CNB showed better concordance with Ki67 in surgical specimens (CR, 82.3%; kappa, 0.639 for digital image analysis vs. CR, 76.2%; kappa, 0.534 for manual counting). The CRs of luminal A, luminal B, HER2, and triple negative types were 89.0%, 70.0%, 82.9%, and 77.2%, respectively.
Conclusions
CNB was reasonably accurate for determining ER, PR, HER2, Ki67, and molecular subtypes. Using digital image analysis for Ki67 in CNB produced more accurate molecular classifications.

Citations

Citations to this article as recorded by  
  • Correlation between ultrasonography and elastography parameters and molecular subtypes of breast cancer in young women
    Dian-xia Men, Hui-zhan Li, Juan Dong, Meng-hua Xue, Zhi-fen Wang, Wen-li Xiao, Ji-ping Xue, Mei-hong Jia
    Annals of Medicine.2025;[Epub]     CrossRef
  • Impact of immunohistochemistry staining conditions on the incidence of human epidermal growth factor receptor 2 (HER2)-low breast cancer
    Min Chong Kim, Sun Young Kwon, Hye Ra Jung, Young Kyung Bae
    Virchows Archiv.2024; 485(6): 1117.     CrossRef
  • Study on Intratumoral Heterogeneity of Expression of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 in Carcinoma Breast
    Ragavi Uthayasuriyan, Sheba K Jacob, Saloni Naresh Shah
    Apollo Medicine.2024; 21(1): 51.     CrossRef
  • Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
    Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park
    Breast Cancer.2024; 31(4): 705.     CrossRef
  • Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature
    Chiara Rossi, Sara Fraticelli, Marianna Fanizza, Alberta Ferrari, Elisa Ferraris, Alessia Messina, Angelica Della Valle, Chiara Annunziata Pasqualina Anghelone, Angioletta Lasagna, Gianpiero Rizzo, Lorenzo Perrone, Maria Grazia Sommaruga, Giulia Meloni, S
    Breast Cancer Research and Treatment.2023; 198(3): 573.     CrossRef
  • Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor
    Su Hwa Kim, Young Suk Lee, Sung Hak Lee, Yeoun Eun Sung, Ahwon Lee, Jun Kang, Jae-Sung Park, Sin Soo Jeun, Youn Soo Lee
    Journal of Pathology and Translational Medicine.2023; 57(4): 217.     CrossRef
  • The Role of Diffusion-Weighted Imaging Based on Maximum-Intensity Projection in Young Patients with Marked Background Parenchymal Enhancement on Contrast-Enhanced Breast MRI
    Ga-Eun Park, Bong-Joo Kang, Sung-hun Kim, Na-Young Jung
    Life.2023; 13(8): 1744.     CrossRef
  • Concordance between core needle biopsy and surgical excision specimens for Ki‐67 in breast cancer – a systematic review of the literature
    Jahnavi Kalvala, Ruth M Parks, Andrew R Green, Kwok‐Leung Cheung
    Histopathology.2022; 80(3): 468.     CrossRef
  • İnvaziv Meme Kanserinde Preoperatif Kor İğne Biyopsi ile Postoperatif Cerrahi Spesmenler Arasında ER, PR, HER2 ve Ki67 Açısından Karşılaştırma
    Pınar CELEPLİ, Pelin Seher ÖZTEKİN, Salih CELEPLİ, İrem BİGAT, Sema HÜCÜMENOĞLU
    Akdeniz Medical Journal.2022; : 179.     CrossRef
  • Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience
    Jessica A. Slostad, Nicole K. Yun, Aimee E. Schad, Surbhi Warrior, Louis F. Fogg, Ruta Rao
    Cancer Medicine.2022; 11(24): 4954.     CrossRef
  • N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas
    Tiemo S. Gerber, Benjamin Goeppert, Anne Hausen, Hagen R. Witzel, Fabian Bartsch, Mario Schindeldecker, Lisa-Katharina Gröger, Dirk A. Ridder, Oscar Cahyadi, Irene Esposito, Matthias M. Gaida, Peter Schirmacher, Peter R. Galle, Hauke Lang, Wilfried Roth,
    Cancers.2022; 14(13): 3091.     CrossRef
  • Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
    Shuai Li, Xiaosong Chen, Kunwei Shen
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • MRI Features for Prediction Malignant Intra-Mammary Lymph Nodes: Correlations with Mammography and Ultrasound
    Meejung Kim, Bong Joo Kang, Ga Eun Park
    Investigative Magnetic Resonance Imaging.2022; 26(2): 135.     CrossRef
  • A single centre experience in Turkey for comparison between core needle biopsy and surgical specimen evaluation results for HER2, SISH, estrogen receptors and progesterone receptors in breast cancer patients
    Hatice Karaman, Fatma Senel, Arzu Tasdemir, Ipek Özer, Merve Dogan
    Journal of Cancer Research and Therapeutics.2022; 18(6): 1789.     CrossRef
  • Meme kanseri trucut ve rezeksiyon materyallerinde yeni moleküler sınıflama, tanı ve hormon reseptörlerinin durumu tutarlı mı?
    Yeliz ARMAN KARAKAYA, Sevda YILMAZ, Hande KARABAŞ
    Pamukkale Medical Journal.2021;[Epub]     CrossRef
  • What shear wave elastography parameter best differentiates breast cancer and predicts its histologic aggressiveness?
    Hyunjin Kim, Jeongmin Lee, Bong Joo Kang, Sung Hun Kim
    Ultrasonography.2021; 40(2): 265.     CrossRef
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
    Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
    Cancer Treatment Reviews.2021; 99: 102229.     CrossRef
  • Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
    Kristina A. Tendl-Schulz, Fabian Rössler, Philipp Wimmer, Ulrike M. Heber, Martina Mittlböck, Nicolas Kozakowski, Katja Pinker, Rupert Bartsch, Peter Dubsky, Florian Fitzal, Martin Filipits, Fanny Carolina Eckel, Eva-Maria Langthaler, Günther Steger, Mich
    Virchows Archiv.2020; 477(4): 545.     CrossRef
Article image
Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma
Jin Hwan Lee, Han Kyeom Kim, Bong Kyung Shin
J Pathol Transl Med. 2020;54(1):103-111.   Published online November 13, 2019
DOI: https://doi.org/10.4132/jptm.2019.10.12
  • 6,549 View
  • 139 Download
  • 6 Web of Science
  • 5 Crossref
AbstractAbstract PDF
Background
Adenocarcinoma (ADC) of the lung exhibits different clinicopathological characteristics in men and women. Recent studies have suggested that these differences originate from the expression of female sex hormone receptors in tumor cells. The aim of the present study was to evaluate the immunohistochemical expression of female sex hormone receptors in lung ADC and determine the expression patterns in patients with different clinicopathological characteristics.
Methods
A total of 84 patients with lung ADC who underwent surgical resection and/or core biopsy were recruited for the present study. Immunohistochemical staining was performed for estrogen receptor α (ERα), estrogen receptor β (ERβ), progesterone receptor (PR), epidermal growth factor receptor (EGFR), EGFR E746- A750 del, and EGFR L858R using tissue microarray.
Results
A total of 39 (46.4%) ERα-positive, 71 (84.5%) ERβ-positive, and 46 (54.8%) PR-positive lung ADCs were identified. In addition, there were 81 (96.4%) EGFR-positive, 14 (16.7%) EGFR E746-A750 del–positive, and 34 (40.5%) EGFR L858R–positive cases. The expression of female sex hormone receptors was not significantly different in clinicopathologically different subsets of lung ADC.
Conclusions
Expression of female sex hormone receptors is not associated with the prognosis and clinicopathological characteristics of patients with lung ADC.

Citations

Citations to this article as recorded by  
  • Molecular characteristics of non-small cell lung cancer tissue based on quantitative indicators of progesterone receptors expression
    I. P. Romanov, T. A. Bogush, A. M. Scherbakov, A. A. Alimov, E. A. Bogush, A.  B. Ravcheeva, A. Lee, V. S. Kosorukov
    Antibiot Khimioter = Antibiotics and Chemotherapy.2024; 69(1-2): 29.     CrossRef
  • Genes Co-Expressed with ESR2 Influence Clinical Outcomes in Cancer Patients: TCGA Data Analysis
    Julia Maria Lipowicz, Agnieszka Malińska, Michał Nowicki, Agnieszka Anna Rawłuszko-Wieczorek
    International Journal of Molecular Sciences.2024; 25(16): 8707.     CrossRef
  • Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review
    Carmine Valenza, Francesca Maria Porta, Alessandra Rappa, Elena Guerini-Rocco, Giuseppe Viale, Massimo Barberis, Filippo de Marinis, Giuseppe Curigliano, Chiara Catania
    Current Oncology.2021; 28(5): 3384.     CrossRef
  • Development of a 15‐Gene Signature Model as a Prognostic Tool in Sex Hormone‐Dependent Cancers
    Zhi Xia, Jian Xiao, Aibin Liu, Qiong Chen, Arumugam R. Jayakumar
    BioMed Research International.2021;[Epub]     CrossRef
  • Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer
    Nuria Mederos, Alex Friedlaender, Solange Peters, Alfredo Addeo
    ESMO Open.2020; 5(Suppl 4): e000796.     CrossRef
Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma
Amany Salama, Mohammad Arafa, Eman ElZahaf, Abdelhadi Mohamed Shebl, Azmy Abd El-Hameed Awad, Sylvia A. Ashamallah, Reda Hemida, Anas Gamal, Abd AlRahman Foda, Khaled Zalata, El-Said M. Abdel-Hady
J Pathol Transl Med. 2019;53(3):164-172.   Published online February 28, 2019
DOI: https://doi.org/10.4132/jptm.2019.02.12
  • 9,307 View
  • 358 Download
  • 12 Web of Science
  • 9 Crossref
AbstractAbstract PDF
Background
In order to improve the efficacy of endometrial carcinoma (EC) treatment, identifying prognostic factors for high risk patients is a high research priority. This study aimed to assess the relationships among the expression of estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, and the different histopathological prognostic parameters in EC and to assess the value of these in the management of EC.
Methods
We examined 109 cases of EC. Immunohistochemistry for ER, PR, HER2, and Ki-67 were evaluated in relation to age, tumor size, International Federation of Gynecology and Obstetrics (FIGO) stage and grade, depth of infiltration, cervical and ovarian involvement, lymphovascular space invasion (LVSI), and lymph node (LN) metastasis.
Results
The mean age of patients in this study was 59.8 ± 8.2 years. Low ER and PR expression scores and high Ki-67 expression showed highly significant associations with non-endometrioid histology (p = .007, p < .001, and p < .001, respectively) and poor differentiation (p = .007, p < .001, and p <. 001, respectively). Low PR score showed a significant association with advanced stage (p = .009). Low ER score was highly associated with LVSI (p = .006), and low PR scores were associated significantly with LN metastasis (p = .026). HER2 expression was significantly related to advanced stages (p = .04), increased depth of infiltration (p = .02), LVSI (p = .017), ovarian involvement (p = .038), and LN metastasis (p = .038). There was a close relationship between HER2 expression and uterine cervical involvement (p = .009). Higher Ki-67 values were associated with LN involvement (p = .012).
Conclusions
The over-expression of HER2 and Ki-67 and low expression of ER and PR indicate a more malignant EC behavior. An immunohistochemical panel for the identification of high risk tumors can contribute significantly to prognostic assessments.

Citations

Citations to this article as recorded by  
  • Multiparameter MRI-based radiomics analysis for preoperative prediction of type II endometrial cancer
    Yingying Cao, Wei Zhang, Xiaorong Wang, Xiaojing Lv, Yaping Zhang, Kai Guo, Shuai Ren, Yuan Li, Zhongqiu Wang, Jingya Chen
    Heliyon.2024; 10(12): e32940.     CrossRef
  • Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors
    Asem Shalaby, Ola Shalaby, Hazem Abdullah, Mohamed Rachid Boulassel, Mohammad Arafa
    Clinical and Translational Oncology.2024; 27(2): 699.     CrossRef
  • Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated With Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma
    Rajni Chibbar, Sabrina Foerstner, Janarathnee Suresh, Richa Chibbar, Alexandre Piche, Deeksha Kundapur, Rani Kanthan, Vijayanand Kundapur, Cheng Han Lee, Anita Agrawal, Raymond Lai
    Applied Immunohistochemistry & Molecular Morphology.2023; 31(3): 181.     CrossRef
  • Exploring the Prognostic and Predictive Roles of Ki-67 in Endometrial Cancer
    Laura Paleari, Mariangela Rutigliani, Oriana D’Ecclesiis, Sara Gandini, Irene Maria Briata, Tania Buttiron Webber, Nicoletta Provinciali, Andrea DeCensi
    International Journal of Translational Medicine.2023; 3(4): 479.     CrossRef
  • Analysis of human epidermal growth factor receptor 2 immunohistochemical expression in high-grade endometrial carcinomas and its association with variable clinical outcomes
    Malames M. Faisal, Marwa M. Shakweer, Ghada Refaat, Khaled S. Mohammed, Tarek I. ElMallawy, Magda H. Nasreldin, Laila M. Farid, Mariam B. Abouelkhair
    Egyptian Journal of Pathology.2023; 43(2): 119.     CrossRef
  • Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma
    Mohammad Arafa, Abdelhadi Mohamed Shebl, Amany Salama, Eman ElZahaf, Sylvia A. Ashamallah, Abd AlRahman Foda, AzmyAbd El-Hameed Awad, Asem Shalaby
    European Journal of Obstetrics & Gynecology and Reproductive Biology: X.2022; 16: 100172.     CrossRef
  • Immunohistochemical Expression of Oestrogen and Epidermal Growth Factor Receptors in Endometrial Cancerous in Sudanese Patients
    Salwa Abdalraheem Abubaker, Mohamed Elfatih Abdelwadoud, Mutaz Mohamed Ali, Hadia Alhaj Ahmad, Abuobieda Mohamed Khlafalla, Osman Mohammed Elmahi, Hisham Ali Waggiallah
    Journal Of Biochemical Technology.2021; 12(1): 58.     CrossRef
  • Expression of ER/PR Receptor, Her-2/neu, Ki67 and p53 in Endometrial Carcinoma: Clinicopathological Implication and Prognostic Value
    V. B. Shivkumar, Manisha A. Atram, Nitin M. Gangane
    Indian Journal of Gynecologic Oncology.2020;[Epub]     CrossRef
  • Immunohistochemical study of ER, PR, p53 and Ki67 expression in patients with endometrial adenocarcinoma and atypical endometrial hyperplasia
    Rachana Lakhe, Ravi M Swami, Preeti Doshi, Manjiri N Karandikar, Ravindra Nimbargi
    IP Archives of Cytology and Histopathology Research.2020; 5(4): 274.     CrossRef
Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
Sung Joo Kim, Soyeon An, Jae Hoon Lee, Joo Young Kim, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
J Pathol Transl Med. 2017;51(4):388-395.   Published online June 8, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.19
  • 7,635 View
  • 136 Download
  • 17 Web of Science
  • 16 Crossref
AbstractAbstract PDF
Background
Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic neoplasms and there is no well-elucidated biomarker to stratify their detection and prognosis. Previous studies have reported that progesterone receptor (PR) expression status was associated with poorer survival in PanNET patients.
Methods
To validate previous studies, PR protein expression was assessed in 21 neuroendocrine microadenomas and 277 PanNETs and compared with clinicopathologic factors including patient survival.
Results
PR expression was gradually decreased from normal islets (49/49 cases, 100%) to neuroendocrine microadenoma (14/21, 66.6%) to PanNETs (60/277, 21.3%; p < .001). PanNETs with loss of PR expression were associated with increased tumor size (p < .001), World Health Organization grade (p = .001), pT classification (p < .001), perineural invasion (p = .028), lymph node metastasis (p = .004), activation of alternative lengthening of telomeres (p = .005), other peptide hormonal expression (p < .001) and ATRX/DAXX expression (p = .015). PanNET patients with loss of PR expression (5-year survival rate, 64.1%) had significantly poorer recurrence-free survival outcomes than those with intact PR expression (90%) by univariate (p = .012) but not multivariate analyses. Similarly, PanNET patients with PR expression loss (5-year survival rate, 76%) had significantly poorer overall survival by univariate (p = .015) but not multivariate analyses.
Conclusions
Loss of PR expression was noted in neuroendocrine microadenomas and was observed in the majority of PanNETs. This was associated with increased grade, tumor size, and advanced pT and pN classification; and was correlated with decreased patient survival time by univariate but not multivariate analyses. Loss of PR expression can provide additional information on shorter disease-free survival in PanNET patients.

Citations

Citations to this article as recorded by  
  • Sex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases
    Mohamed Mortagy, Marie Line El Asmar, Kandiah Chandrakumaran, John Ramage
    Cancers.2024; 16(13): 2376.     CrossRef
  • Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors
    Jeremy Chang, Mohammed O. Suraju, Catherine G. Tran, Carlos H.F. Chan, Po Hien Ear, James R. Howe, Scott K. Sherman
    Journal of Surgical Research.2024; 302: 53.     CrossRef
  • Incidence and Prognostic Implications of Lymphovascular Invasion in Node‐Negative Pancreatic Neuroendocrine Tumors: Results From the US Neuroendocrine Study Group
    Kota Sahara, Diamantis I. Tsilimigras, Yuki Homma, Jun Kawashima, Shishir K. Maithel, Flavio Rocha, Sharon Weber, Ryan Fields, Kamran Idrees, George A. Poultsides, Cliff Cho, Itaru Endo, Timothy M. Pawlik
    Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm
    Sho Kiritani, Junichi Arita, Yuichiro Mihara, Rihito Nagata, Akihiko Ichida, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa
    Surgery.2023; 173(2): 365.     CrossRef
  • Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor
    Bokyung Ahn, Joo Young Kim, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2023; 147(1): 100.     CrossRef
  • HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
    Milton J. Barros, Jonathan Strosberg, Taymeyah Al-Toubah, Victor Hugo F. de Jesus, Lais Durant, Celso A. Mello, Tiago C. Felismino, Louise De Brot, Rodrigo G. Taboada, Mauro D. Donadio, Rachel P. Riechelmann
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors
    Florian Viehweger, Lisa-Marie Tinger, David Dum, Natalia Gorbokon, Anne Menz, Ria Uhlig, Franziska Büscheck, Andreas M. Luebke, Claudia Hube-Magg, Andrea Hinsch, Doris Höflmayer, Christoph Fraune, Patrick Lebok, Sören Weidemann, Maximilian Lennartz, Frank
    Analytical Cellular Pathology.2022; 2022: 1.     CrossRef
  • Prognostic Nomograms to Predict Overall Survival and Cancer-Specific Survival of Patients With Pancreatic Neuroendocrine Tumors
    Zuoli Song, Sumei Wang, Yujing Wu, Jinjuan Zhang, Shuye Liu
    Pancreas.2021; 50(3): 414.     CrossRef
  • Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
    Haeryoung Kim, Soyeon An, Kyoungbun Lee, Sangjeong Ahn, Do Youn Park, Jo-Heon Kim, Dong-Wook Kang, Min-Ju Kim, Mee Soo Chang, Eun Sun Jung, Joon Mee Kim, Yoon Jung Choi, So-Young Jin, Hee Kyung Chang, Mee-Yon Cho, Yun Kyung Kang, Myunghee Kang, Soomin Ahn
    Cancer Research and Treatment.2020; 52(1): 263.     CrossRef
  • Systemic distribution of progesterone receptor subtypes in human tissues
    Teeranut Asavasupreechar, Ryoko Saito, Yasuhiro Miki, Dean P. Edwards, Viroj Boonyaratanakornkit, Hironobu Sasano
    The Journal of Steroid Biochemistry and Molecular Biology.2020; 199: 105599.     CrossRef
  • Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms
    Tomoyoshi Tachibana, Atsuko Kasajima, Takeshi Aoki, Tomoaki Tabata, Keely McNamara, Samaneh Yazdani, Sato Satoko, Fumiyoshi Fujishima, Fuyuhiko Motoi, Michiaki Unno, Hironobu Sasano
    The Journal of Steroid Biochemistry and Molecular Biology.2020; 201: 105694.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • Immunohistochemistry, carcinomas of unknown primary, and incidence rates
    Edward B. Stelow, Hadi Yaziji
    Seminars in Diagnostic Pathology.2018; 35(2): 143.     CrossRef
  • Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival
    Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong
    Virchows Archiv.2018; 472(5): 739.     CrossRef
  • Prognostic value of progesterone receptor in solid pseudopapillary neoplasm of the pancreas: evaluation of a pooled case series
    Feiyang Wang, Zibo Meng, Shoukang Li, Yushun Zhang, Heshui Wu
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • Estrogens modulate progesterone receptor expression and may contribute to progesterone-mediated apoptotic β-cell death
    Viviane Abreu Nunes
    Endocrinology&Metabolism International Journal.2018;[Epub]     CrossRef
Higher Expression of Toll-like Receptors 3, 7, 8, and 9 in Pityriasis Rosea
Mostafa Abou El-Ela, Mohamed El-Komy, Rania Abdel Hay, Rehab Hegazy, Amin Sharobim, Laila Rashed, Khalda Amr
J Pathol Transl Med. 2017;51(2):148-151.   Published online February 13, 2017
DOI: https://doi.org/10.4132/jptm.2016.09.09
  • 7,372 View
  • 100 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDF
Background
Pityriasis rosea (PR) is a common papulosquamous skin disease in which an infective agent may be implicated. Toll-like receptors (TLRs) play an important role in immune responses and in the pathophysiology of inflammatory skin diseases. Our aim was to determine the possible roles of TLRs 3, 7, 8, and 9 in the pathogenesis of PR. Methods: Twenty-four PR patients and 24 healthy individuals (as controls) were included in this case control study. All recruits were subjected to routine laboratory investigations. Biopsies were obtained from one active PR lesion and from healthy skin of controls for the detection of TLR 3, 7, 8, and 9 gene expression using real-time polymerase chain reaction. Results: This study included 24 patients (8 females and 16 males) with active PR lesions, with a mean age of 28.62 years. Twenty four healthy age- and sex-matched individuals were included as controls (8 females and 16 males, with a mean age of 30.83 years). The results of the routine laboratory tests revealed no significant differences between both groups. Significantly elevated expression of all studied TLRs were detected in PR patients relative to healthy controls (p < .001). Conclusions: TLRs 3, 7, 8, and 9 might be involved in the pathogenesis of PR.

Citations

Citations to this article as recorded by  
  • Toll-like Receptor-Mediated Immunomodulation of Th1-Type Response Stimulated by Recombinant Antigen of Type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-2)
    Rika Wahyuningtyas, Mei-Li Wu, Wen-Bin Chung, Hso-Chi Chaung, Ko-Tung Chang
    Viruses.2023; 15(3): 775.     CrossRef
  • Pityriasis Rosea: An Updated Review
    Alexander K.C. Leung, Joseph M. Lam, Kin Fon Leong, Kam Lun Hon
    Current Pediatric Reviews.2021; 17(3): 201.     CrossRef
  • Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea
    Sidharth Sonthalia, Akshy Kumar, Vijay Zawar, Adity Priya, Pravesh Yadav, Sakshi Srivastava, Atula Gupta
    Journal of Dermatological Treatment.2018; 29(6): 617.     CrossRef
P2X7 Receptor Expression in Coexistence of Papillary Thyroid Carcinoma with Hashimoto's Thyroiditis
Ji Hyun Kwon, Eun Sook Nam, Hyung Sik Shin, Seong Jin Cho, Hye Rim Park, Mi Jung Kwon
Korean J Pathol. 2014;48(1):30-35.   Published online February 25, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.1.30
  • 9,811 View
  • 54 Download
  • 21 Crossref
AbstractAbstract PDF
Background

This study was aimed at investigating the relation of P2X7 receptor (P2X7R) expression with the clinicopathological features of papillary thyroid carcinoma (PTC) coexisting with Hashimoto's thyroiditis (HT).

Methods

We examined 170 patients (84, PTC with HT; 86, PTC without HT). P2X7R expression was examined by immunohistochemical methods. The staining intensity and patterns were evaluated and scored using a semi-quantitative method.

Results

The PTC with HT group was more likely to contain women and had less extrathyroid extension, lymph node (LN) metastasis, lymphovascular invasion, and recurrence than the PTC without HT group. Patients positive for P2X7R had significantly higher frequencies of lymphovascular invasion, extrathyroid extension, LN metastasis, and absence of HT. As shown by multivariate analysis, the expression of P2X7R was significantly higher if HT was absent and extrathyroid extension was present. In the PTC with HT group, the expression of P2X7R was significantly higher in patients with tumor multifocality, lymphovascular invasion, and extrathyroid extension. In the PTC without HT group, the expression of P2X7R was significantly higher in women and those having tumor multifocality.

Conclusions

Coexistence of PTC with HT is associated with good prognostic factors, and P2X7R expression in PTC was correlated with poor prognostic factors and the absence of HT.

Citations

Citations to this article as recorded by  
  • Research Progress in the Relationship Between P2X7R and Cervical Cancer
    Yiqing Tang, Cuicui Qiao, Qianqian Li, Xiaodi Zhu, Ronglan Zhao, Xiaoxiang Peng
    Reproductive Sciences.2023; 30(3): 823.     CrossRef
  • Warthin-like papillary thyroid carcinoma: a case report and comprehensive review of the literature
    Abdel Mouhaymen Missaoui, Fatma Hamza, Wafa Belabed, Manel Mellouli, Mohamed Maaloul, Slim Charfi, Issam Jardak, Tahya Sellami-Boudawara, Nabila Rekik, Mohamed Abid
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Mapping the path towards novel treatment strategies: a bibliometric analysis of Hashimoto’s thyroiditis research from 1990 to 2023
    Manping Guo, Qingna Li, Xingfang Liu, Yiming Wang, Qiaoning Yang, Rui Li, Yang Zhao, Chenfei Li, Song Sheng, Hangkun Ma, Zhenghong Li, Rui Gao
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
    Qizhi Tang, Weiyu Pan, Liangyue Peng, Francis Moore
    PLOS ONE.2022; 17(6): e0269995.     CrossRef
  • Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
    Peter P. Issa, Mahmoud Omar, Yusef Buti, Chad P. Issa, Bert Chabot, Christopher J. Carnabatu, Ruhul Munshi, Mohammad Hussein, Mohamed Aboueisha, Mohamed Shama, Ralph L. Corsetti, Eman Toraih, Emad Kandil
    Biomedicines.2022; 10(8): 2051.     CrossRef
  • Overexpression of PD-L1 in Papillary Carcinoma and Its Association with Clinicopathological Variables
    Servet KOCAÖZ, Gülay TURAN
    Düzce Tıp Fakültesi Dergisi.2021; 23(3): 252.     CrossRef
  • Effect of P2X7 receptor on tumorigenesis and its pharmacological properties
    Wen-jun Zhang, Ce-gui Hu, Zheng-ming Zhu, Hong-liang Luo
    Biomedicine & Pharmacotherapy.2020; 125: 109844.     CrossRef
  • P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
    Romain Lara, Elena Adinolfi, Catherine A. Harwood, Mike Philpott, Julian A. Barden, Francesco Di Virgilio, Shaun McNulty
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
    Luiz E. B. Savio, Paola de Andrade Mello, Cleide Gonçalves da Silva, Robson Coutinho-Silva
    Frontiers in Pharmacology.2018;[Epub]     CrossRef
  • Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls
    Azadeh A. Carr, Tina W.F. Yen, Diana I. Ortiz, Bryan C. Hunt, Gilbert Fareau, Becky L. Massey, Bruce H. Campbell, Kara L. Doffek, Douglas B. Evans, Tracy S. Wang
    Thyroid.2018; 28(11): 1462.     CrossRef
  • Extracellular purines, purinergic receptors and tumor growth
    F Di Virgilio, E Adinolfi
    Oncogene.2017; 36(3): 293.     CrossRef
  • Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives
    Paola de Andrade Mello, Robson Coutinho-Silva, Luiz Eduardo Baggio Savio
    Frontiers in Immunology.2017;[Epub]     CrossRef
  • Potential role of P2X7R in esophageal squamous cell carcinoma proliferation
    André A Santos, Angélica R Cappellari, Fernanda O de Marchi, Marina P Gehring, Aline Zaparte, Caroline A Brandão, Tiago Giuliani Lopes, Vinicius D da Silva, Luis Felipe Ribeiro Pinto, Luiz Eduardo Baggio Savio, Aline Cristina Abreu Moreira-Souza, Robson C
    Purinergic Signalling.2017; 13(3): 279.     CrossRef
  • Potential relationship between Hashimoto's thyroiditis and BRAFV600E mutation status in papillary thyroid cancer
    Rui‐chao Zeng, Lang‐ping Jin, En‐dong Chen, Si‐yang Dong, Ye‐feng Cai, Guan‐li Huang, Quan Li, Chun Jin, Xiao‐hua Zhang, Ou‐chen Wang
    Head & Neck.2016;[Epub]     CrossRef
  • Papillary thyroid carcinoma in Hashimoto’s thyroiditis as an incidental finding
    Al Mogrampi Saad, A. Krexi, N. Papoulidis, M. Verroiotou, D. Michalakis, I. Fardellas
    Hellenic Journal of Surgery.2016; 88(1): 47.     CrossRef
  • Association of Hashimoto's thyroiditis and thyroid cancer
    Salem I. Noureldine, Ralph P. Tufano
    Current Opinion in Oncology.2015; 27(1): 21.     CrossRef
  • Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation
    Mi Jung Kwon, Young-Soo Rho, Jin Cheol Jeong, Hyung Sik Shin, Jong Seok Lee, Seong Jin Cho, Eun Sook Nam
    Human Pathology.2015; 46(8): 1180.     CrossRef
  • Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives
    Sébastien Roger, Bilel Jelassi, Isabelle Couillin, Pablo Pelegrin, Pierre Besson, Lin-Hua Jiang
    Biochimica et Biophysica Acta (BBA) - Biomembranes.2015; 1848(10): 2584.     CrossRef
  • Purinergic signaling pathways in endocrine system
    Ivana Bjelobaba, Marija M. Janjic, Stanko S. Stojilkovic
    Autonomic Neuroscience.2015; 191: 102.     CrossRef
  • P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway
    JIYI XIA, XIAOLAN YU, LI TANG, GANG LI, TAO HE
    Oncology Reports.2015; 34(1): 103.     CrossRef
  • Regulation of the P2X7R by microRNA-216b in human breast cancer
    Luming Zheng, Xukui Zhang, Feng Yang, Jian Zhu, Peng Zhou, Fang Yu, Lei Hou, Lei Xiao, Qingqing He, Baocheng Wang
    Biochemical and Biophysical Research Communications.2014; 452(1): 197.     CrossRef
Case Report
Cystic Nephroma: A Case Report and Comparing Literature Review with Mixed Epithelial and Stromal Tumor of Kidney.
Hyun Jung Kim, Choong Hee Noh, Giyoung Kwon, Eunah Shin, Jung Yeon Kim, Kyeongmee Park
Korean J Pathol. 2011;45:S25-S28.
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.S1.S25
  • 3,121 View
  • 37 Download
AbstractAbstract PDF
Cystic nephroma (CN) is a benign cystic neoplasm composed of mixed epithelial and stromal elements. Less than 200 cases have been reported. We had a patient, a 41-year-old woman, who had a huge typical CN. The patient was admitted for a right renal mass that was found incidentally. On laparaoscopic right nephrectomy, there was an encapsulated 7 cm multilocular cystic mass at the upper pole. Microscopically, the cystic wall was lined by a single layer of low cuboidal or hobnail epithelium without a solid area. The thin septa were composed of bland, ovarian type spindle cells. The main differential diagnoses were mixed epithelial and stromal tumor (MEST), low grade multilocular renal cell carcinoma, and tubulocystic carcinoma. The results of immunohistochemical staining were cytokeratin 7/19(+/+) and CD10(-) in lining epithelium, estrogen receptor/progesterone receptor(+/+) in stromal cells. After surgery, she was free of recurrence for 10 months. We report this rare case and compare it with other cystic renal tumors, especially MEST.
Original Articles
An Approach to Diagnosing Gastrointestinal Stromal Tumors Using Immunohistochemistry of c-kit and PDGFRA with Molecular Analysis.
Jeong Shik Kim, Jae Hoon Kim, Hyun Jin Oh, In Soo Suh, Jong Gwang Kim, Byung Wook Kang, Wan Sik Yu, Ho Young Chung, Han Ik Bae
Korean J Pathol. 2010;44(2):173-178.
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.2.173
  • 3,359 View
  • 39 Download
AbstractAbstract PDF
BACKGROUND
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors in the gastrointestinal tract. Recently, many methods for the diagnosis of GIST have been developed including molecular diagnosis.
METHODS
We selected 90 cases of GIST that had presented at Kyungpook National University Hospital between 1998 and 2007. Tissue microarrays were made using core areas of tumor tissues. Immunohistochemical staining for c-kit, protein kinase C-theta, and platelet-derived growth factor receptor alpha (PDGFRA) was done. Direct sequencing of hot spot exonal areas for c-kit and PDGFRA were done using extracted DNAs of all 90 paraffin block tissues.
RESULTS
Among the 90 cases, 83.3% (75/90) were c-kit positive, 16.6% (15/90) were c-kit negative, 93.3% (84/90) were PDGFRA positive, and 6.6% (6/90) cases were PDGFRA negative. Fifteen cases of c-kit negative GIST included 1 case of PDGFRA negative and 5 cases of PDGFRA negative GIST were ckit positive. The one case in which both c-kit and PDGFRA were negative, showed a c-kit mutation in exon 11.
CONCLUSIONS
Combined immunohistochemical staining of c-kit, discovered on GIST 1 (DOG1) and PDGFRA is helpful for the diagnosis of GIST. When all staining tests are negative for immunoreactivity, c-kit mutation analysis for exon 11, 9 should be done. Genotyping of kit and PDGFRA do not need to be examined initially, if it is only for the diagnosis of GIST.
Expression of Androgen Receptor, bcl-2 Protein and Rb Protein in Breast Cancers as Related to Prognostic Factors.
Hyun Deuk Cho, Young Sik Kim, Insun Kim
Korean J Pathol. 1998;32(6):443-452.
  • 1,727 View
  • 10 Download
AbstractAbstract
Breast cancer is the most common malignancy of women in industrialized countries and the third in Korean women. There have been a lot of studies on biologic behaviors as well as on the prognostic factors of the breast cancer. In this study, the expression of hormone receptors (estrogen receptor ; ER, progesterone receptor ; PR, and androgen receptor ; AR), bcl-2 and Rb proteins were immunostained on 60 infiltrating ductal carcinomas of the breast. The results were evaluated in relation with the age, histologic grade, tumor size, and status of lymph node metastasis. The expression of ER and PR had a significant inverse correlation with the histologic grade (p<0.001). The expression of AR was significantly correlated with the expression of ER (p=0.039) and PR (p=0.009), but not with other factors such as age, histologic grade, tumor size, and status of lymph node metastasis. There was no relationship between bcl-2 protein expresssion and other prognostic factors, except with the expression of ER. Rb protein expression had a significant positive relationship with PR (p=0.05) and the degree of positivity was correlated with histologic grade (p=0.002). In conclusion, this result suggests that expression of AR is well correlated with ER and PR. bcl-2 has no prognostic value. The significance of Rb protein expression remained to be studied.
The Expression of Transforming Growth Factor-1 and Its Signaling Receptors in Human Colorectal Carcinoma.
Gyeong Seon Kim, Joo Heon Kim, Woo Sung Moon, Myoung Ja Chung, Dong Geun Lee, Myoung Jae Kang
Korean J Pathol. 2001;35(2):115-122.
  • 1,808 View
  • 14 Download
AbstractAbstract PDF
BACKGROUND
Resistance to the potent growth inhibitory effects of TGF- (transforming growth factor-) is a characteristic of many malignancies. TGF- insensitivity has been attributed to alterations in the number and function of the TGF- receptors as well as disturbances of downstream signal transduction. The aim of this study was to examine the expression of TGF-1 and its receptors in human colorectal cancer tissue and determine its relationship with cancer growth and with prognostic factors.
METHODS
Immunohistochemical staining of TGF-1, TGF-RI, and TGF-RII was performed on 20 human colorectal adenomas, 30 carcinomas and 10 normal mucosas as a control.
RESULTS
The staining indices of TGF-1, TGF-RI, and TGF-RII increased in adenomas and carcinomas compared with normal mucosas and adenomas, respectively. In adenomas the staining index of TGF-1 significantly increased with the severity of atypism. The staining index of TGF-RII increased in the carcinomas in the right colon and rectum, compared with those in the left colon.
CONCLUSION
The enhanced expression of TGF-1, TGF-RI and II in the colorectal carcinoma suggests an important role of colorectal carcinogenesis and tumor progression.
Association of CXCR4 Expression with Metastasis and Survival among Patients with Non-small Cell Lung Cancer.
Joon Seon Song, Jin Kyung Jung, Jong Chul Park, Dong Kwan Kim, Se Jin Jang
Korean J Pathol. 2008;42(6):358-364.
  • 1,950 View
  • 25 Download
AbstractAbstract PDF
BACKGROUND
Expression of CXCR4 chemokine receptor, initially described to be involved in the homing of lymphocytes in inflammatory tissue, on breast cancer cell lines is associated with the development of lung metastases. In the present study, we evaluated CXCR4 expression in patients with non-small cell lung cancer (NSCLC). METHODS: Tissue microarray blocks were constructed from 408 formalin-fixed, paraffin-embedded NSCLC samples and analyzed via immunohistochemical staining. RESULTS: We observed CXCR4 expression in 214 (66.3%) of the 323 tumors with cytoplasmic or nuclear staining patterns. These tumors were then divided into 109 negative, 166 weak-positive and 48 strong-positive expression groups. Strong expression of CXCR4 correlated with NSCLC recurrence (p=0.047) and distant metastasis (p=0.035). However, lymph node metastasis (p=0.683) and locoregional recurrence (p=0.856) were not associated with CXCR4 expression. Interestingly, the median overall survival times relative to CXCR4 expression were 71 months in the CXCR4-negative group, 43 months in the weakly positive CXCR4 group and 23 months in the strongly positive CXCR4 group. Strongly positive CXCR4 staining was associated with significantly worse outcomes (p=0.005, log-rank test).
CONCLUSIONS
Expression of CXCR4 was associated with distant NSCLC metastases and shorter survival times.
PPARgamma Ligand-Induced Decrease of in vivo Tumor Growth Accompanied by Increased Cytolytic Activity of Splenocytes.
Kyu Yun Jang, Ki Hoon Yu, Hak Yong Lee, Kyung Ryoul Kim, Ha Na Choi, Eun Jung Cha, Ho Sung Park, Woo Sung Moon, Myoung Jae Kang, Dong Geun Lee
Korean J Pathol. 2007;41(1):7-14.
  • 1,745 View
  • 22 Download
AbstractAbstract PDF
BACKGROUND
Recent studies have proposed the use of peroxisome proliferator activated receptor-gamma (PPARgamma) ligands as new chemotherapeutic agents for human malignant tumors. However the in vivo mechanism of PPARgamma ligands on cellular toxicity is not clear. Therefore we examined the anti-tumor effects of the PPARgamma ligand, rosiglitazone (ROS), in animal models.
METHODS
To evaluate the effect of RSO on splenocytes, an in vitro and in vivo study was performed. Cytolytic activity was measured by use of a 51Cr release assay. The splenic natural killer (NK) cell population and effector-target conjugation were measured by flow cytometric analysis.
RESULTS
In 9L glioma bearing rats, 30 mg/kg/d of ROS treatment induced a significant decrease of subcutaneous tumor growth accompanied by an increased cytolytic activity of splenocytes and of the splenic NKR-P1bright/CD3- NK cell population. In normal rats, systemic administration of ROS also increased the cytolytic activity of splenocytes, the splenic NK cell population, and effector-target conjugation. Moreover, we found that a concentration of 20micrometer ROS caused an increase in the cytolytic activity of splenocytes, and a concentration of 50micrometer ROS increased effector-target conjugation in vitro.
CONCLUSIONS
These results suggest that increased splenic cytolytic activity and NK cell population may contribute to the anti-tumor effects of PPARgamma ligands in vivo. However, the roles of NK cells in the PPARgamma ligand-induced anti-tumor activity should be further investigated.
The Expressions of Tyrosine Kinase Receptors, EphA2, c-met and c-erbB-2 in the Human Breast.
Soo Kee Min, Hyun Deuk Cho, Seong Jin Cho, Hye Rim Park, Hyung Sik Shin, Young Euy Park, Bom Woo Yeom
Korean J Pathol. 2005;39(1):15-22.
  • 1,843 View
  • 22 Download
AbstractAbstract PDF
BACKGROUND
Tyrosine kinase receptor (TKR) is an important protein for normal-development, growth and tumorigenesis in human tissues. The purpose of this study was to evaluate the effect of TKR in the progression of breast cancer.
METHODS
The expressions of EphA2, c-met and c-erbB-2 were examined, by using immunohistochemical methods and RT-PCR, in samples of breast tissue that included 111 samples of normal epithelium, 34 samples of ductal carcinoma in situ (DCIS), and 109 samples of invasive ductal carcinomas (IDC). The results were compared with the prognostic parameters of breast cancer including the tumor grade, growth pattern, lymph node metastasis and the expressions of ER, PR, p53 and Ki-67.
RESULTS
The protein expressions of the three TKRs were higher in DCIS and IDC than in normal epithelium. The protein expression of EphA2 was correlated with a tumor grade, a labeling index of Ki-67, and the protein expression of c-met. Overexpression of c-erbB-2 was correlated with lymph node metastasis. The mRNA levels of the three TKRs were correlated with each other in normal tissue and IDC. The level of c-met mRNA was higher in the low grade tumors.
CONCLUSIONS
The three TKRs may play roles in the tumorigenesis of human breast cancer. The overexpressions of EphA2 and c-erbB-2 may be a poor prognostic parameter in breast cancers.
Relationship between Immunohistochemical Expression of Cathepsin D and Other Prognostic Factors of Breast Carcinoma.
Kwang Hwa Park, Byeng Woo Park, Kyong Sik Lee, Kwang Gil Lee
Korean J Pathol. 1994;28(6):612-619.
  • 1,699 View
  • 20 Download
AbstractAbstract PDF
The cathepsin D is a lysosomal protease secreted in excess by breast cancer cells. The function of this enzyme is degradation of the extracellular matrix and proteoglycan. It is induced by estrogens in estrogen receptor positive breast cancer cell lines. On the basis of this, cathepsin D expression in breast cancer cells seems to be correlated with the prognosis. But there is debates in its prognostic significance. Relationship between cathepsin D expression and other prognostic factors of breast cancer was studied. We investigated 51 cases of invasive ductal cell carcinoma of breast removed by open biopsy or mastectomy. All cases were fixed in formalin and embedded in paraffin. We used 46-KD intermediate form of the enzyme for cathepsin D expression on immunohistochemical stain. We observed no significant correlation with age, stage, histologic grade, lymphatic invasion, and estrogen receptor status. Cathepsin D may be an independent factor which is not related with other prognostic factors, especially estrogen receptor status.

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP